Drugs / TB006
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04920786 | Jun 2021 → May 2022 | Alzheimer disease | TrueBinding, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04801056 | Jun → Sep 2021 | COVID-19 | TrueBinding, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT05074498 | Oct 2021 → Oct 2022 | Alzheimer disease | TrueBinding, Inc. | Completed | Missed primary |
| Phase 24 trials | ||||||
| Phase 2 | NCT06773962 | Mar 2025 → Nov 2026 expected | Parkinson disease | TrueBinding, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06500637 | Aug 2024 → Dec 2026 expected | autism spectrum disorder | Rossignol Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05476783 | Sep 2022 → Nov 2023 | Alzheimer disease | TrueBinding, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05156827 | Jul 2022 → Dec 2023 | ischemic stroke | TrueBinding, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT05959239 | — | Alzheimer disease | TrueBinding, Inc. | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TB006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05476783 ↗ |
| Action | Inhibit | “To inhibit Gal-3's contribution to neuroinflammation” NCT06500637 ↗ |
| Modality | Monoclonal antibody | “TB006, a monoclonal antibody” NCT04801056 ↗ |
| Route | Intravenous | “administered via i.v. infusion” NCT04801056 ↗ |